ClearPoint Neuro, Inc. (CLPT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$13.96-0.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CLPT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Adjust 2026 revenue guidance to $48M-$52M reflecting strategic investments in clinical support and product development.
Stated as a priority in 3 of last 3 quarters. Revenue guidance for 2026 was initially set between $52.0M and $56.0M in 2026-Q1 and 2025-Q4, then adjusted downward to $48.0M-$52.0M in 2026-Q2 reflecting strategic investments. Actual revenue grew from $8.5M in 2025-Q1 to $12.1M in 2026-Q1 but guidance revision indicates a more cautious outlook. The trajectory shows management recalibrating expectations consistent with stated priorities.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We are adjusting our 2026 revenue guidance to between $48.0 - $52.0 million.”
“The Company estimates revenue in 2026 to be between $52.0 million and $56.0 million.”
“For 2026, we now expect revenues to be in the range of $52.0 - $56.0 million.”
Advance clinical trials and regulatory approvals with over 60 active biopharma partners to enable commercial cell and gene therapy delivery.
Stated as a priority in 2 of last 2 quarters. Management highlights ongoing progress with over 60 active biopharma partners advancing clinical trials and regulatory submissions, aiming for commercial approvals by 2027. While no specific revenue or milestone numbers are cited, the recurring emphasis and partner count indicate sustained focus and moderate progress.
“Continued clinical trial and regulatory progress across more than 60 active biopharma partners.”
“Continued clinical trial and regulatory progress across more than 60 active biopharma partners.”
Continue integration of IRRAS product portfolio and team to realize revenue growth and cost synergies, targeting cash neutrality in 2027.
Stated as a priority in 2 of last 2 quarters. Management reports measurable revenue and cost synergies from IRRAS integration, with combined 2026 revenue guidance initially at $54.0-$60.0M. Actual revenue grew from $8.5M in 2025-Q1 to $12.1M in 2026-Q1, reflecting integration progress. The trajectory shows ongoing integration efforts with expected cash neutrality in 2027.
“Achievement of measurable revenue and cost synergies through the continuing integration of the IRRA flow product portfolio and team.”
“The total 2026 combined revenue for the two companies is expected to be in the range of $54.0 to $60.0 million.”
Invest in clinical capacity expansion and reorganize commercial structure to support drug delivery readiness for anticipated 2027 approvals.
Newly stated in 2026-Q2. Management emphasized investment in clinical capacity and commercial reorganization to prepare for commercial drug delivery readiness in 2027. No direct financial metrics yet available, indicating early-stage execution with planned future impact.
“Investing in building our clinical capacity so that the ClearPoint installed base and clinical support team are not a bottleneck.”
Advance development and commercialization of focused ultrasound system, robotic platform, and Harmony 1.0 software to support global scale.
Newly stated in 2026-Q2. Management introduced strategic development of focused ultrasound, robotic platform, and Harmony 1.0 software. This is an early-stage priority with no current revenue or milestone data, reflecting a strategic product expansion focus.
“Announced plans to enter focused ultrasound market and showcased robotic platform and Harmony 1.0 software.”
Over the trailing year it converted 0.79x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
12 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.